A ~$4.5B share repurchase program adds further value. LIBTAYO demonstrated massive growth, accelerating to 50% in Q4 2024 versus Q4 2023. Approval in CSCC means that this growth catalyst is ...

In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...

The camp will end with the exhibition match involving Filipinas players to be held at the newly-completed MOA Football Field, a rare opportunity for the Filipino fans to watch the team at home.

while preserving the heritage and cultural elements,” Loke said after witnessing the signing of a signing of a memorandum of agreement (MoA) on the project between Ipoh Sentral Sdn Bhd (ISSB ...

Cancer treatment decisions are complex, requiring consideration of both medical advancements and individual patient needs, including emotional and physical conditions. There is often a gap between the ...

Phase 3 trial shows promising pain relief for acute pain patients Tris Pharma, Inc. has announced positive results from its ALLEVIATE-1 phase 3 clinical trial evaluating cebranopadol for treating ...

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT (amivantamab) for the first-line treatment of adult patients with advanced ...